**Author details**

Giuseppe Lo Giudice San Paolo Ophthalmic Center, San Antonio Hospital, Padua, Italy

\*Address all correspondence to: giuseppe.logiudice@aulss6.veneto.it

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**139**

*Introductory Chapter: Macular Degeneration: Mechanisms of Action*

expression profile of human retinal pigment epithelium. Current Eye Research. 2006;**31**:181-189

[9] Glenn JV, Mahaffy H, Dasari S, Oliver M, Chen M, Boulton ME, et al. Proteomic profiling of human retinal pigment epithelium exposed to an advanced glycation-modified substrate.

Graefe's archive for clinical and

2011;**32**:1407-1416

experimental ophthalmology. Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie.

[10] Rohrer B, Long Q, Coughlin B, Wilson RB, Huang Y, Qiao F, et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Investigative Ophthalmology & Visual

Science. 2009;**50**:3056-3064

[11] Thurman JM, Renner B, Kunchithapautham K, Ferreira VP, Pangburn MK, Ablonczy Z, et al. Oxidative stress renders retinal pigment epithelial cells susceptible to complement mediated injury. The Journal of Biological Chemistry.

2009;**284**:16939-16947

2003;**131**:248-253

[13] Bhutto IA, McLeod DS,

[12] Fukuoka Y, Strainic M, Medof ME. Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a. Clinical and Experimental Immunology.

Hasegawa T, Kim SY, Merges C, Tong P, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age related macular degeneration. Experimental Eye Research. 2006;**82**:99-110

[14] Cherepanoff S, McMenamin P, Gillies MC, Kettle E, Sarks SH. Bruch's

*DOI: http://dx.doi.org/10.5772/intechopen.86739*

[1] Bird AC. Therapeutic targets in age-related macular disease. The Journal of Clinical Investigation.

[2] Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BE. The epidemiology of retinal reticular drusen. American

[3] Klein ML, Ferris FL 3rd, Francis PJ, Lindblad AS, Chew EY, Hamon SC, et al. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology.

[4] Zweifel SA, Imamura Y, Spaide TC, Fujiwara T, Spaide RF. Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration. Ophthalmology. 2010;**117**:1775-1781

Essing AH, van der Spek PJ, et al. A new strategy to identify and annotate human RPE-specific gene expression. PLoS

[6] Newman AM, Gallo NB, Hancox LS, Miller NJ, Radeke CM, Maloney MA, et al. Systems-level analysis of agerelated macular degeneration reveals global biomarkers and phenotypespecific functional networks. Genome

[7] Kurji KH, Cui JZ, Lin T, Harriman D, Prasad SS, Kojic L, et al. Microarray analysis identifies changes in

inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. Investigative Ophthalmology & Visual

**References**

2010;**120**:3033-3041

2008;**145**:317-326

2010;**117**:1554-1559

[5] Booij JC, ten Brink JB, Swagemakers SM, Verkerk AJ,

ONE. 2010;**5**:e9341

Medicine. 2012;**4**:16

Science. 2010;**51**:1151-1163

[8] Cai H, Del Priore LV. Bruch membrane aging alters the gene

Journal of Ophthalmology.

*Introductory Chapter: Macular Degeneration: Mechanisms of Action DOI: http://dx.doi.org/10.5772/intechopen.86739*
